Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi is running a global registry called “Atopic ...
Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment.
Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on ...
Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...
Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
Two large deals and an acquisition, all totaling about $4.64 billion, are helping close out a strong year. Yarrow Bioscience Inc. cut a potentially $1.36 billion deal with Shanghai Scizeng Medical ...
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting ...
Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback